Burn patients who received GLP-1 receptor agonists within 30 days of injury had significantly lower rates of infection, mortality, readmission, and opioid prescriptions at 90 days and 1 year.
Lower opioid useBurn patients on GLP-1 drugs had significantly fewer opioid prescriptions at both 90 days and 1 year
What the researchers found
At 90 days, GLP-1 RA users had significantly lower rates of soft tissue infection, opioid prescriptions, readmission, and mortality (all p<0.05), with benefits persisting at 1 year for opioids, readmission, and mortality.
Why it matters
Burns cause severe inflammation, pain, and high complication rates. If GLP-1 drugs can reduce infections and opioid dependence after burns, they could become an important addition to burn care protocols.
How the study worked
Retrospective propensity-matched cohort study using TriNetX electronic health records with 3,231 patients per group matched on demographics, comorbidities, and burn characteristics.
What this study cannot tell us
Retrospective observational design. Patients on GLP-1 drugs may have better baseline health. Cannot determine if GLP-1 drugs directly caused better outcomes. No significant wound healing improvements (scarring, contractures).
How to read the evidence
Large propensity-matched retrospective study with consistent findings across multiple timepoints and outcomes. Observational design limits causal inference.
When this study was published
Published in 2025, exploring a novel application of GLP-1 drugs in burn care.
The bigger picture
This adds to growing evidence that GLP-1 peptide drugs have systemic anti-inflammatory and tissue-protective effects beyond metabolic control, with potential applications in acute injury and critical care settings.
Questions still open
- What biological mechanisms explain GLP-1 drugs' protective effects in burn patients?
- Could GLP-1 drugs reduce opioid dependence after burns through direct reward pathway modulation?
- Should GLP-1 drugs be prospectively tested as standard adjunct therapy in burn care?
Common questions
How could a diabetes drug help burn patients?
Did GLP-1 drugs help burns heal better?
Read the original research
Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.
Burns : journal of the International Society for Burn Injuries, 52(2), 107848
Citation
Dao, Matthew Q; Kim, Anika Y; Wang, Sarah; Won, Paul; Laspro, Matteo; Gillenwater, T Justin; Yenikomshian, Haig A; Johnson, Maxwell B. (2026). Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.. Burns : journal of the International Society for Burn Injuries, 52(2), 107848. https://doi.org/10.1016/j.burns.2025.107848